STATCenter·
STAT+: FDA pauses Regenxbio gene therapy trial again due to safety concerns
The FDA put a hold on a Regenxbio gene therapy trial again after new safety concerns emerged.
Read at STAT →
Health · 1 sources covering this
STAT+: FDA pauses Regenxbio gene therapy trial again due to safety concerns
The FDA put a hold on a Regenxbio gene therapy trial again after new safety concerns emerged.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/d196841e5153be4e0805c3a45f295b4e10d80260" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: FDA pauses Regenxbio gene therapy trial again due to safety concerns"></iframe>
